Platelet activating factor involvement in splanchnic artery occlusion shock in rats

Area of Science:

• Physiology
• Pathology
• Pharmacology

Background:

• Splanchnic artery occlusion shock is a critical condition with high mortality.
• The role of platelet-activating factor (PAF) in this shock model requires further elucidation.

Purpose of the Study:

• To investigate the involvement of PAF in splanchnic artery occlusion shock.
• To evaluate the therapeutic potential of a PAF receptor antagonist (L-652,731) in this shock model.

Main Methods:

• Splanchnic artery occlusion shock was induced in anesthetized rats.
• Plasma levels of thromboxane B2 (TxB2) and 6-keto-PGF1 alpha, and serum/macrophage tumor necrosis factor alpha (TNF alpha) were measured.
• Macrophage phagocytic and killing activity, and white blood cell count were assessed.
• Rats were treated with the PAF antagonist L-652,731.

Main Results:

• Shocked rats exhibited increased plasma TxB2 and 6-keto-PGF1 alpha, elevated TNF alpha, reduced macrophage activity, and leukopenia.
• L-652,731 significantly improved survival rates, lowered TxB2 and TNF alpha levels, restored macrophage function, and inhibited leukopenia.
• The antagonist also ameliorated cardiovascular changes associated with the shock.

Conclusions:

• Platelet-activating factor (PAF) is implicated in the pathophysiology of splanchnic artery occlusion shock.
• PAF contributes to shock through direct actions and indirectly via thromboxane B2 (TxB2) and tumor necrosis factor alpha (TNF alpha).
• PAF receptor antagonism with L-652,731 demonstrates significant therapeutic benefits in this shock model.